The trial will assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of BW-50218 in participants.

A University of Kentucky Martin-Gatton College of Agriculture, Food and Environment researcher is leading a new project that ...

Wave Life Sciences recently released its latest 10-Q report. The company is a clinical-stage biotechnology firm based in ...

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 ...

Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follo ...

By tracking immune RNA fragments, researchers identified new mosquito viruses, and showed how some evade detection, offering ...

AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one ...

The EMA’s April meeting of the Medicinal Products for Human Use Committee (CHMP) recommended five new medicines and nine ...